Rasa Pelanis1, Jan Roar Mellembakken1, Inger Sundström-Poromaa2, Pernille Ravn3, Laure Morin-Papunen4,5, Juha S Tapanainen4,5,6, Terhi Piltonen4,5, Johanna Puurunen4,5, Angelica Lindén Hirschberg7,8, Peter Fedorcsak1,9, Marianne Andersen10, Dorte Glintborg10. 1. Department of Reproductive Medicine, Division of Gynecology and Obstetrics, Oslo University Hospital, Oslo, Norway. 2. Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. 3. Department of Gynaecology and Obstetrics, Odense University Hospital, Odense, Denmark. 4. Department of Obstetrics and Gynaecology, Oulu University Hospital, University of Oulu. 5. Medical Research Centre and PEDEGO Research Unit for Paediatrics, Dermatology, Clinical Genetics, Obstetrics and Gynaecology, Oulu, Finland. 6. Department of Obstetrics and Gynaecology, Helsinki University Hospital and University of Helsinki. 7. Department of Women's and Children's Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 8. Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden. 9. Faculty of Medicine, University of Oslo, Oslo, Norway. 10. Department of Endocrinology, Odense University Hospital, Kløvervænget 6, 6th floor, DK-5000 Odense C, Odense, Denmark.
Abstract
STUDY QUESTION: Is oral glucose tolerance test (OGTT) needed in all women with polycystic ovary syndrome (PCOS)? SUMMARY QNSWER: OGTT is not routinely needed in women with PCOS and BMI < 25 kg/m2. WHAT IS KNOWN ALREADY: PCOS is associated with insulin resistance and increased prevalence of prediabetes and Type 2 diabetes (T2D) which is closely linked to obesity and possibly age, ethnicity and PCOS phenotype. Several guidelines recommend OGTT upon diagnosis of PCOS and during follow-up. STUDY DESIGN, SIZE, DURATION: A Nordic cross-sectional study including 876 women. PARTICIPANTS/MATERIALS, SETTING, METHODS: The 876 Nordic women with PCOS, aged 14-57 years, were examined for T2D and prediabetes (impaired glucose tolerance [IGT] or impaired fasting glucose (IFG) by OGTT. MAIN RESULT AND THE ROLE OF CHANCE: Of all study subjects 3% (23/876) had T2D, 23% (204/876) prediabetes and 74% (649/876) had normal glucose tolerance (NGT). Increased BMI and waist circumference were significantly (P < 0.001) associated with prevalence of prediabetes and T2D. No normal-weight woman (BMI < 25 kg/m2) was diagnosed with T2D. The prevalence of BMI ≥ 25 kg/m2 was 66% (578/ 876). 91% of women (21/23) with T2D had BMI ≥ 30 kg/m2. Testosterone levels and PCOS phenotype did not predict 2-h glucose levels during OGTT after adjustment for BMI and age. LIMITATIONS, REASONS FOR CAUTION: The present study included cross-sectional data and prospective studies are needed to confirm our results. These results may not apply to populations of other ethnic origin. WIDER IMPLICATIONS OF THE FINDINGS: Routine OGTT may not be indicated in normal-weight women with PCOS. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: N/A.
STUDY QUESTION: Is oral glucose tolerance test (OGTT) needed in all women with polycystic ovary syndrome (PCOS)? SUMMARY QNSWER: OGTT is not routinely needed in women with PCOS and BMI < 25 kg/m2. WHAT IS KNOWN ALREADY: PCOS is associated with insulin resistance and increased prevalence of prediabetes and Type 2 diabetes (T2D) which is closely linked to obesity and possibly age, ethnicity and PCOS phenotype. Several guidelines recommend OGTT upon diagnosis of PCOS and during follow-up. STUDY DESIGN, SIZE, DURATION: A Nordic cross-sectional study including 876 women. PARTICIPANTS/MATERIALS, SETTING, METHODS: The 876 Nordic women with PCOS, aged 14-57 years, were examined for T2D and prediabetes (impaired glucose tolerance [IGT] or impaired fasting glucose (IFG) by OGTT. MAIN RESULT AND THE ROLE OF CHANCE: Of all study subjects 3% (23/876) had T2D, 23% (204/876) prediabetes and 74% (649/876) had normal glucose tolerance (NGT). Increased BMI and waist circumference were significantly (P < 0.001) associated with prevalence of prediabetes and T2D. No normal-weight woman (BMI < 25 kg/m2) was diagnosed with T2D. The prevalence of BMI ≥ 25 kg/m2 was 66% (578/ 876). 91% of women (21/23) with T2D had BMI ≥ 30 kg/m2. Testosterone levels and PCOS phenotype did not predict 2-h glucose levels during OGTT after adjustment for BMI and age. LIMITATIONS, REASONS FOR CAUTION: The present study included cross-sectional data and prospective studies are needed to confirm our results. These results may not apply to populations of other ethnic origin. WIDER IMPLICATIONS OF THE FINDINGS: Routine OGTT may not be indicated in normal-weight women with PCOS. STUDY FUNDING/COMPETING INTEREST(S): None. TRIAL REGISTRATION NUMBER: N/A.
Authors: Ramon Bossardi Ramos; Lucas Bandeira Marchesan; Poli Mara Spritzer; Monica de Oliveira; Enrico Carmina Journal: Diabetol Metab Syndr Date: 2021-02-16 Impact factor: 3.320
Authors: Balachandran Kumarendran; Michael W O'Reilly; Anuradhaa Subramanian; Dana Šumilo; Konstantinos Toulis; Krishna M Gokhale; Chandrika N Wijeratne; Arri Coomarasamy; Abd A Tahrani; Laurent Azoulay; Wiebke Arlt; Krishnarajah Nirantharakumar Journal: Diabetes Care Date: 2021-10-14 Impact factor: 19.112
Authors: Noel Yat Hey Ng; Guozhi Jiang; Lai Ping Cheung; Yuying Zhang; Claudia Ha Ting Tam; Andrea On Yan Luk; Jianchao Quan; Eric Siu Him Lau; Tiffany Tse Ling Yau; Michael Ho Ming Chan; Chung Shun Ho; Cadmon King Poo Lim; Risa Ozaki; Jin Huang; Kin Hung Liu; Wing Hung Tam; Daljit Singh Sahota; Winnie Chiu Wing Chu; William Goggins; Jean Woo; Tin Chiu Li; Chun Chung Chow; Juliana Chung Ngor Chan; Ronald Ching Wan Ma Journal: PLoS Med Date: 2019-10-25 Impact factor: 11.069